Renal Osteodystrophy: A Comprehensive Overview

Definition

• Osteitis fibrosa - high-turnover disease from hyperparathyroidism
• Osteomalacia - defective mineralization, often aluminum-related
• Adynamic bone disease (ABD) - abnormally low bone turnover
• Mixed renal osteodystrophy - combinations of the above
• Osteopenia/Osteoporosis

The Spectrum of Skeletal Abnormalities

Fig. 88.1 - Spectrum of Renal Osteodystrophy. The skeletal abnormalities range from low-turnover (adynamic bone disease/osteomalacia, driven by calcium, calcitriol, and aluminum) to high-turnover (osteitis fibrosa, driven by hyperparathyroidism), with mixed disease in between. (Comprehensive Clinical Nephrology, 7th Ed.)

KDIGO TMV Classification

Etiology and Pathogenesis

Fig. 26.11 - Mechanisms of renal osteodystrophy. Metabolic abnormalities and altered endocrine signaling between bone and kidney. (Robbins, Cotran & Kumar Pathologic Basis of Disease)

1. Calcium Metabolism Disturbances

• Total serum calcium falls as GFR decreases due to phosphate retention, decreased renal 1,25-(OH)2D3 synthesis, reduced intestinal calcium absorption, and skeletal resistance to PTH
• Free calcium levels stay normal initially due to compensatory hyperparathyroidism
• Persistent hypocalcemia is a powerful continuous stimulus for PTH hypersecretion and parathyroid gland hyperplasia

2. Phosphate Retention and FGF-23

• With progressive CKD, the kidney retains phosphate (hyperphosphatemia becomes overt at stage 4 CKD)
• Early compensation involves increased FGF-23 (secreted by osteocytes), which promotes phosphaturia - but this comes at the cost of suppressing 1α-hydroxylase, further reducing calcitriol synthesis
• Decreased renal expression of Klotho (the FGF-23 co-receptor) impairs phosphate handling, creates FGF-23 resistance, and directly suppresses calcitriol

3. Vitamin D Deficiency

• The kidney performs the crucial second hydroxylation step (25-OH-D → 1,25-(OH)2D3, calcitriol)
• Impaired calcitriol synthesis → reduced intestinal Ca2+ absorption → hypocalcemia → elevated PTH
• Calcitriol also directly suppresses PTH gene transcription and is needed for osteoblast/osteoclast maturation

4. Secondary Hyperparathyroidism (High-Turnover Disease)

• The combined effects of hypocalcemia, hyperphosphatemia, calcitriol deficiency, and Klotho reduction drive parathyroid hyperplasia
• Parathyroid glands show decreased expression of Vitamin D receptors, calcium-sensing receptors, and α-Klotho
• An elevated "set-point" for calcium-regulated PTH secretion develops
• PTH drives increased osteoclast and osteoblast activity → osteitis fibrosa

5. Tubular Dysfunction and Acidosis

• Tubular and systemic acidosis increases RANKL expression on osteoblasts → increased osteoclast recruitment and bone matrix resorption → osteopenia
• Acidosis also impairs mineralization

6. Aluminum Toxicity (Low-Turnover Disease)

• Historically, aluminum-containing phosphate binders and aluminum-contaminated dialysate were major causes
• Aluminum deposits at the mineralization front, blocking further hydroxyapatite crystal growth → osteomalacia
• Aluminum also directly suppresses osteoblast activity → adynamic bone disease

7. Adynamic Bone Disease - Low-Turnover

• Increasingly prevalent, especially in diabetic and elderly dialysis patients, and those on peritoneal dialysis
• Caused by over-suppression of PTH (excess calcium/vitamin D supplementation), aluminum toxicity, diabetes mellitus, and aging
• Characterized by absent or minimal osteoblast/osteoclast activity - the bone cannot respond to microfractures

8. β2-Microglobulin Amyloidosis (Aβ2M)

• In long-term dialysis patients (>10 years), β2-microglobulin accumulates and deposits as amyloid in synovial membranes, joints, and bone, causing destructive arthropathy and cyst formation

Pathology

Histological Types

Fig. 88.11 - Bone Histology in Renal Osteodystrophy. (A) Osteitis fibrosa: increased multinucleated osteoclasts and osteoblast activity with peritrabecular fibrosis (stained blue, arrow). (B) Adynamic bone disease: no cellular activity, no osteoid. (C) Mixed ROD: active osteoclasts on one surface (arrowhead) with thickened osteoid (asterisk) on another. (D) Osteomalacia: marked excess of unmineralized osteoid (red) around mineralized bone (blue). (Comprehensive Clinical Nephrology, 7th Ed.)

• Increased osteoclast AND osteoblast numbers and activity
• Peritrabecular fibrosis (replacement of marrow by fibrous tissue)
• Woven (disorganized) osteoid rather than lamellar
• In severe cases: brown tumors (collections of osteoclasts, fibroblasts, and hemosiderin-laden macrophages in lytic cavities)

• Increased osteoid seam width (unmineralized bone matrix accumulates)
• Increased trabecular surface covered by osteoid
• Decreased bone mineralization (assessed by tetracycline double-labeling)
• Von Kossa stain: mineralized bone = black; osteoid = magenta/red

Fig. 16.10 - Osteomalacia in renal osteodystrophy. (A) Von Kossa stain: previously formed bone black; newly synthesized unmineralized osteoid magenta. All surfaces covered with thick osteoid seams. (B) Same field stained with solochrome azurine to detect aluminum (dark-blue line at the mineralization front - aluminum blocks further mineralization). (Henry's Clinical Diagnosis & Management by Laboratory Methods)

• Aluminum staining >15% of the trabecular surface
• Bone formation rate <220 mm²/day

• No osteoclastic or osteoblastic cellular activity
• No osteoid visible on biopsy
• Bone cannot respond to microdamage → fragility fractures

Fig. 16.9 - Renal osteodystrophy with hyperparathyroidism and osteomalacia. Von Kossa method: mineralized bone = black; osteoid = Alizarin red. Arrows point to cutting cones of osteoclasts tunneling into mineralized bone through the few remaining mineralized surfaces. The red (osteoid) areas are smooth and devoid of osteoclasts. (Henry's Clinical Diagnosis & Management)

Epidemiology

• Skeletal abnormalities can begin at eGFR ~50 mL/min/1.73 m2 (CKD stage 3)
• In hemodialysis patients: osteitis fibrosa is declining, ABD is increasing (especially in White patients)
• In Black dialysis patients: osteitis fibrosa remains dominant
• In peritoneal dialysis patients, diabetics, and elderly: ABD has been dominant for decades
• Osteomalacia represents a small fraction but is more common in South Asians Comprehensive Clinical Nephrology, 7th Ed., p. 1180

Signs and Symptoms

Skeletal Manifestations

• Bone pain - non-specific aches and pains in the lower back, hips, and legs; aggravated by weight-bearing; can be debilitating
• Acute localized bone pain - may mimic acute arthritis
• Pathological fractures - especially of long bones; vertebral fractures cause kyphoscoliosis or chest deformities
• Subperiosteal erosions - on radiographs, particularly at radial aspect of middle phalanges (classic site)
• Resorption of terminal digits (acro-osteolysis)
• Brown tumors - lytic lesions, can be confused with bone metastases
• Slipped epiphyses - particularly in children
• Growth retardation - in children with CKD
• Deformities - resulting from fractures and bone softening

Muscle and Joint Manifestations

• Proximal muscle weakness - gradual onset; multifactorial (PTH excess, vitamin D deficiency, uremic myopathy)
• Periarthritis - peri-articular calcium phosphate crystal deposition, especially with hyperphosphatemia; mimics gout or pseudogout; responds to NSAIDs
• Carpal tunnel syndrome and destructive arthropathy - in β2-microglobulin amyloidosis (long-term dialysis)

Extraskeletal Calcifications

• Vascular calcification - arterial wall calcification; major contributor to cardiovascular mortality
• Pulmonary calcification - can cause restrictive lung disease
• Myocardial calcification
• Periarticular calcification - "tumoral calcinosis" pattern
• Calciphylaxis (calcific uremic arteriolopathy) - rare but life-threatening; painful skin necrosis from calcification of small dermal vessels

Fig. 88.7 - Extraskeletal Calcification in Kidney Failure. (A) Arterial calcification (arrows). (B) Pulmonary calcification - bilateral nodular opacities. (C) Periarticular calcification at the shoulder (arrows). (Comprehensive Clinical Nephrology, 7th Ed.)

Skin Manifestations

• Pruritus - related to hyperparathyroidism and calcium-phosphate deposition in skin
• Calciphylaxis causes painful, necrotic skin lesions with a livedo pattern

Investigations

1. Serum Biochemistry

• Two-site immunometric ("intact" PTH) assays also measure large N-terminally truncated fragments
• "Biointact" PTH (1-84) assays are more specific but not clearly superior clinically
• KDIGO target for dialysis patients: iPTH approximately 2-9x the upper limit of normal for the assay used
• Serial PTH measurements are essential - trends are as important as absolute values
• In CKD stages 3-5, progressive rises above normal should be addressed

2. Radiological Investigations

• Subperiosteal bone resorption at radial aspect of middle phalanges (pathognomonic of hyperparathyroidism)
• Salt and pepper skull - granular mottling from patchy resorption
• Rugger jersey spine - alternating bands of sclerosis and lucency
• Brown tumors - well-defined lytic lesions
• Looser's zones / pseudofractures - linear lucencies perpendicular to the cortex in osteomalacia
• Acro-osteolysis - resorption of terminal phalanges
• Periosteal reaction (in children)
• Vascular and soft tissue calcifications

• Measures bone mineral density (BMD)
• Does not distinguish between types of ROD
• Useful for monitoring osteopenia/osteoporosis

• Increased uptake in areas of high turnover or calcification
• Can identify brown tumors and soft tissue calcification sites

3. Bone Biopsy (Gold Standard)

• Bone turnover - via dynamic tetracycline-based measurements (bone formation rate, activation frequency)
• Mineralization - osteoid volume, osteoid thickness, mineralization lag time
• Bone volume - trabecular bone volume per tissue volume
• Aluminum - stained with solochrome azurine or Perl's stain; >15% trabecular surface = aluminum-related disease

• PTH in the recommended range but bone-specific ALP is elevated
• Hypercalcemia with only modestly elevated PTH
• Significant bone pain without clear biochemical cause
• Before parathyroidectomy when etiology is uncertain

4. Other Tests

• Serum β2-microglobulin - elevated in amyloidosis
• MRI of joints - for β2-microglobulin amyloid deposits (destructive spondyloarthropathy)
• Parathyroid ultrasound / Sestamibi scan - for tertiary hyperparathyroidism, pre-surgical localization
• Serum aluminum level and deferoxamine stimulation test - if aluminum toxicity suspected

Treatment

1. Dietary Modification

• Phosphate restriction: Limit dairy products, processed foods with added phosphate, and protein-rich foods (but avoid <0.8 g/kg/day protein to prevent malnutrition)
• Calcium supplementation: Calcium carbonate taken between meals as the initial approach to hypocalcemia in mild-moderate CKD

2. Control of Phosphate (Cornerstone of Management)

3. Vitamin D Therapy

• 25-hydroxyvitamin D deficiency (<30 ng/mL): Correct with ergocalciferol or cholecalciferol
• Active vitamin D sterols (calcitriol, alfacalcidol, paricalcitol, doxercalciferol): Used in CKD 3-5D when PTH remains elevated despite correction of hypocalcemia and vitamin D deficiency
• These directly suppress PTH gene transcription and reduce parathyroid hyperplasia
• Selective vitamin D receptor activators (paricalcitol): Have less hypercalcemia and hyperphosphatemia than calcitriol; may have additional cardiovascular benefits
• Goal in dialysis patients: Achieve iPTH ~2-9x the upper limit of normal (to avoid over-suppression and ABD)

4. Calcimimetics

• Cinacalcet (oral), etelcalcetide (IV, administered with dialysis), evocalcet (Japan): Target the calcium-sensing receptor, increasing its sensitivity to calcium → reduces PTH secretion
• Especially useful when PTH is elevated with concurrent hypercalcemia or hyperphosphatemia (since calcimimetics lower Ca and P as well as PTH)
• Can be combined with low-dose active vitamin D for synergistic effect
• Side effects: Hypocalcemia, nausea/vomiting (less with etelcalcetide on nausea profile)
• Cinacalcet significantly reduces rates of parathyroidectomy and calciphylaxis
• Not recommended in pre-dialysis CKD due to phosphate retention risk

5. Treatment of Adynamic Bone Disease

• Reduce or stop calcium supplements
• Reduce active vitamin D doses
• Allow PTH to rise slightly to stimulate bone formation
• Avoid oversuppression of PTH below target ranges

6. Treatment of Aluminum-Related Bone Disease

• Eliminate aluminum exposure (switch phosphate binders)
• Deferoxamine (DFO) chelation therapy: Binds aluminum and promotes its dialytic removal; indicated when serum aluminum is markedly elevated or aluminum staining on biopsy is significant. Risk of serious infections (mucormycosis) limits its use.

7. Treatment of β2-Microglobulin Amyloidosis

• High-flux dialysis membranes and hemodiafiltration enhance β2-microglobulin clearance
• Renal transplantation - restores normal kidney function and halts amyloid deposition

8. Parathyroidectomy

• Severe, refractory hyperparathyroidism failing medical therapy (iPTH often >1000 pg/mL)
• Persistent hypercalcemia from autonomous parathyroid function (tertiary hyperparathyroidism)
• Calciphylaxis with elevated PTH (urgent indication)
• Severe metastatic calcification
• Before kidney transplantation with significant osteopenia or frank hypercalcemia

• Subtotal parathyroidectomy (3.5 glands removed)
• Total parathyroidectomy with autotransplantation (forearm muscle)

9. Renal Transplantation

• The most effective long-term treatment for all forms of renal osteodystrophy
• Restores calcitriol production, phosphate regulation, and suppresses PTH
• Post-transplant bone loss in the first year is common due to corticosteroid immunosuppression
• Persistent hyperparathyroidism for up to 12 months post-transplant is expected; mild hypercalcemia may resolve spontaneously

Summary Table: Key Features by ROD Type

• Comprehensive Clinical Nephrology, 7th Ed., Chapter 88 (CKD-MBD and Renal Osteodystrophy)
• Robbins, Cotran & Kumar Pathologic Basis of Disease (Metabolic Diseases of Bone)
• Henry's Clinical Diagnosis and Management by Laboratory Methods (Metabolic Bone Disease)
• Brenner and Rector's The Kidney (CKD-MBD, TMV Classification)
• Grainger & Allison's Diagnostic Radiology (Radiological features of ROD)